The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 11,500.00
Ask: 12,200.00
Change: 0.00 (0.00%)
Spread: 700.00 (6.087%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

Wed, 03rd Jan 2024 07:54

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

This is also ahead of two key data releases in the US later, particularly the latest meeting minutes from the US Federal Reserve this evening, which will provide investors insight into the central bank's thinking on the future of US interest rates.

Prior to this, the Institute of Supply Management's manufacturing PMI for the US is released in the afternoon.

"Markets turned cautious ahead of today's [Federal Open Market Committee] minutes, US JOLT's job openings number, and the ISM manufacturing index. Markets have rallied over the past few weeks, and the dollar has come under considerable pressure as markets price in six rate cuts by the Fed this year," said TreasuryOne analyst Andre Cilliers.

"The Fed is only forecasting three cuts at this stage, and we saw some short dollar covering yesterday while bonds and equities were sold off."

In UK corporate news, both Wizz Air and Ryanair reported increased passenger numbers in December and across 2023.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called down 1.0 point at 7,720.52

----------

Hang Seng: down 1.4% at 7,523.20

Nikkei 225: financial markets in Japan closed for New Year holiday

S&P/ASX 200: closed down 1.4% at 7,523.20

----------

DJIA: closed up 25.50 points, or 0.1%, at 37,715.04

S&P 500: closed down 27.00 points, or 0.6%, at 4,742.83

Nasdaq Composite: closed down 245.41 points, or 1.6%, to 14,765.94

----------

EUR: up at USD1.0959 (USD1.0955)

GBP: up at USD1.2635 (USD1.2620)

USD: up at JPY142.34 (JPY141.74)

Gold: down at USD2,062.16 per ounce (USD2,064.66)

(Brent): down at USD75.81 a barrel USD77.75)

(changes since previous London equities close)

----------

ECONOMICS

----------

Wednesday's key economic events still to come:

09:55 CET Germany unemployment

10:00 EST US ISM manufacturing PMI

14:00 EST US Federal Reserve meeting minutes

----------

The Israeli army has said it is "prepared for any scenario" after a strike in Beirut that killed Hamas's deputy chief, stoking fears the war in the Gaza Strip could boil over into wider regional conflict. Israeli army spokesperson Daniel Hagari did not directly comment on the killing, but said afterwards that the military was in "very high state of readiness in all arenas, in defence and offence. We are highly prepared for any scenario." Israel has previously announced the deaths in Gaza of Hamas commanders and officials during the war, but Aruri is the most high-profile figure to be killed, and his death came in the first strike on the Lebanese capital since hostilities began.

----------

BROKER RATING CHANGES

----------

Jefferies cuts AstraZeneca to 'hold' (buy) - price target 11,000 (12,500) pence

----------

Jefferies raises GSK to 'buy' (hold) - price target 1,900 (1,550) pence

----------

COMPANIES - FTSE 250

----------

Wizz Air said it carried 5.0 million passengers in December, up 19% from a year earlier, at a load factor of 82% from 85%. Across 2023, it carried 60.3 million passengers, up 32% from 45.7 million in 2022, at a load factor of 91% from 87%. Capacity in December rose 22% to 6.0 million passengers from 5.0 million a year earlier, while across 2023, capacity rose 26% to 66.4 million from 52.7 million. The airline said it continued to grow its network and improve its customer offering in December, including Wizz Air Abu-Dhabi doubling the number of flights to 15,000 and carrying more than three million passengers.

----------

OTHER COMPANIES

----------

Budget airline Ryanair said it carried 12.5 million passengers in December, up 8.7% from 11.5 million passengers a year earlier, at a load factor of 91% from 92%. It said it operated over 72,500 flights in December, while over 900 flights were cancelled due to the Israel/Gaza conflict. Across 2023, it carried 181.8 million passengers, up 13% from 160.4 million in 2022, at a load factor of 94% from 92%.

----------

Drug discovery company C4X Discovery said it has received a milestone payment of USD11 million from FTSE 100-listed pharmaceutical firm AstraZeneca, triggered by pre-clinical progress of C4X Discovery's NFT2 Activator programme. AstraZeneca is developing C4X Discovery's former programme to deliver an oral therapy for the treatment of inflammatory and respiratory diseases, with a lead focus on chronic respiratory disease. As announced under the terms of the licencing agreement in November 2022, C4X Discovery received an initial USD2 million upfront payment from AstraZeneca and is potentially entitled to receive up to USD400 million in preclinical, clinical development and commercial milestones, as well as tiered mid-single digit royalties on future sales. C4X Discovery Clive Dix commented: "This significant preclinical milestone payment marks the progress AstraZeneca has made in driving the NRF2 Activator programme forward. NRF2 is a challenging target and this achievement provides further validation of our ability to generate differentiated, quality molecules in immuno-inflammation."

----------

Chill Brands unveiled product launch plans and regulatory initiatives for the first quarter of 2024. As previously announced, the CBD products company received a number of material purchase orders during the fourth quarter of 2023. It is now in the process of fulfilling those purchase orders and expects to have delivered all initial inventory during January 2024. Chill ZERO nicotine-free vape products will launch into initial WH Smith travel locations, Morrisons stores, and roadside retail stores operating on Shell, BP and Esso branded forecourts during January 2024 with the rollout continuing incrementally throughout the first quarter. Chill Brands said it will also take steps to address regulatory concerns on balancing the "positive impact of vaping as a harm reduction tool with the need to protect children and the environment". It plans to do this by participating in a recycling scheme, to focus on "appropriate merchandising and age verification to ensure express compliance with existing and future regulations at all points of the supply chain", and to use more "conscious" design and flavour choices that indicate its products are "solely intended for adult consumers".

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.